Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Open-label, Dose-escalation and Expansion Study to Assess the Safety, Pharmacokinetics and Clinical Activity of NUC-7738, a Nucleotide Analogue, in Patients With Advanced Solid Tumours and Lymphoma

Next Previous
Trial Profile

A Phase I/II, Open-label, Dose-escalation and Expansion Study to Assess the Safety, Pharmacokinetics and Clinical Activity of NUC-7738, a Nucleotide Analogue, in Patients With Advanced Solid Tumours and Lymphoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NUC 7738 (Primary) ; Pembrolizumab
  • Indications B-cell lymphoma; Colorectal cancer; Gastric cancer; Hodgkin's disease; Lung cancer; Lymphoma; Malignant melanoma; Non-Hodgkin's lymphoma; Skin cancer; Solid tumours; T-cell lymphoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms NuTide: 701
  • Sponsors NuCana

Most Recent Events

  • 20 Mar 2025 According to a NuCana media release, company to initiate an expansion of the Phase 1/2 study (NuTide:701) of NUC-7738 in combination with pembrolizumab in patients with melanoma, announce data from the Phase 1/2 expansion study (NuTide:701) of NUC-7738 in combination with pembrolizumab and to obtain regulatory guidance from the U.S. Food and Drug Administration on pivotal study design for NUC-7738 in melanoma in 2025.
  • 11 Nov 2024 Planned number of patients changed from 94 to 135.
  • 11 Nov 2024 Planned End Date changed from 1 Jun 2024 to 1 Aug 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top